Siltuximab - Janssen Biotech

Drug Profile

Siltuximab - Janssen Biotech

Alternative Names: Anti-interleukin-6 monoclonal antibody - Centocor; cCLB8; Chimeric anti-interleukin-6 monoclonal antibody - Centocor; CNTO-328; Sylvant

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centocor
  • Developer Centocor; Janssen Biotech; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant lymph node hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Giant lymph node hyperplasia
  • Phase II Multiple myeloma
  • No development reported Paraproteinaemia
  • Discontinued Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 18 Jul 2018 Janssen Sciences Ireland enters into an agreement with EUSA Pharma to licenses siltuximab, worldwide
  • 18 Jul 2018 Registered for Giant lymph node hyperplasia in South Korea (IV) before July 2018
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top